2025
Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Isufi I, Crombie J, Frigault M, Andreadis C, Lin Y, Mirza A, Kim S, Bernasconi D, Toron F, Krimmel T, Roy D, Pasquini M, Ahmed S. Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation And Cellular Therapy 2025, 31: s215. DOI: 10.1016/j.jtct.2025.01.329.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeDuration of responseLiso-celNonrelapse mortalityCR rateCenter for International Blood and Marrow Transplant Research (CIBMTR) registryMedian duration of responseCAR-T cell productsLarge B-cell lymphomaB-cell lymphomaClinically significant infectionsB-cell malignanciesT cell productionConsistent with clinical studiesCD19-directedExtranodal involvementLisocabtagene maraleucelNRM ratesProlonged cytopeniasR/R LBCLIndolent lymphomaData cutoffElevated LDHRadiation therapy
2023
Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy
Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.Peer-Reviewed Original ResearchHigh-grade B-cell lymphomaCART-cell therapyProgression-free survivalOverall survivalInferior overall survivalB-cell lymphomaCART cellsCell therapyRetrospective studyEra cohortCell lymphomaBCL6 rearrangementsLarge B-cell lymphomaAnthracycline-based therapySuperior overall survivalMulticenter retrospective studyHigher overall survivalElectronic health recordsAdult ptsPrior chemotherapyYr OSB symptomsBulky diseaseCART eraElevated LDH
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply